Published Date:2024-04-22 Original Link:https://www.onenessbio.com/en/news_detail280_4.htm No 1 Date of announcement 2024/04/22 Time of announcement 18:16:38 Subject Subcutaneous injection formulation of FB825 to treat moderate-to-severe atopic dermatitis was greenlighted by TFDA to proceed with a Ph2 study To which item it meets paragraph 10 Date of events 2024/04/22 Statement Date of occurrence of the event:2024/04/22 New drug...Read More